Acute pharmacodynamic responses to exenatide: Drug‐induced increases in insulin secretion and glucose effectiveness
Authors' conclusion
This pilot study provides validation for the value of a frequently sampled intravenous glucose tolerance test (including minimal model analysis) to provide primary data for our ongoing pharmacogenomic study of pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative assessments of the effects of glucagon-like peptide-1 receptor agonists on glucose metabolism: first phase insulin secretion, glucose disappearance rates and glucose effectiveness.
Study context
- Population
- Healthy volunteerscrossover
- Participants
- 62 volunteers
- Comparison
- Exenatide vs saline
Methodological detailsrandom order
- Random order
Primary result
As reported in the abstract
First phase insulin secretion increased with exenatide
1.9-fold
p = 1.9 × 10-9
Rate of glucose disappearance accelerated with exenatide
2.4-fold
p = 2 × 10-10
Glucose effectiveness (Sg) increased with exenatide (minimal model)
32%
p = .0008
Further findings
Contributions to interindividual variation in exenatide-induced acceleration of glucose disappearance
- Exenatide-induced increase in insulin secretion (largest contribution)
- β = 0.58
- Drug effect on Sg (lesser extent)
- β = 0.27
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →